Baker Bros. Advisors LP Design Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $9.34 Billion
- Q3 2024
A detailed history of Baker Bros. Advisors LP transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 1,743,725 shares of DSGN stock, worth $10.9 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
1,743,725
Previous 1,695,294
2.86%
Holding current value
$10.9 Million
Previous $5.68 Million
65.19%
% of portfolio
0.1%
Previous 0.08%
Shares
8 transactions
Others Institutions Holding DSGN
# of Institutions
102Shares Held
31MCall Options Held
2.3KPut Options Held
16.5K-
Sr One Capital Management, LP6.53MShares$40.8 Million11.88% of portfolio
-
Logos Global Management LP San Francisco, CA4.22MShares$26.4 Million3.0% of portfolio
-
Black Rock Inc. New York, NY2.3MShares$14.4 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.89MShares$11.8 Million0.55% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.6MShares$10 Million0.02% of portfolio
About Design Therapeutics, Inc.
- Ticker DSGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,807,900
- Market Cap $349M
- Description
- Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...